KURA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Kura Oncology Inc (KURA) does not present a compelling buy opportunity for a long-term beginner investor at this time. While the stock has shown slight positive price movement recently and has a favorable analyst rating, the lack of strong technical signals, insider selling, and weak financial performance outweigh the positives. The investor should wait for stronger catalysts or improved financial trends before considering an investment.
The MACD histogram is positive and expanding (0.129), indicating bullish momentum. However, RSI is neutral at 69.533, and moving averages are converging, showing no clear trend. The stock is trading near its first resistance level (R1: 8.683), with limited upward potential in the short term.
Analyst Jason Zemansky maintains a Buy rating with a price target of $29, suggesting significant upside potential.
Gross margin remains strong at 100%.
Insiders are selling, with a 178.01% increase in selling activity over the last month.
Weak financial performance with negative net income (-$74.12M) and EPS (-0.85), despite YoY improvement.
Stock trend analysis indicates a 60% chance of a price decline in the short term (-2.46% next day, -2.32% next week, -3.15% next month).
In Q3 2025, revenue remained flat at $20.75M YoY. Net income improved by 36.23% YoY but remains negative (-$74.12M). EPS improved by 34.92% YoY to -0.85. Gross margin is strong at 100%. Overall, financials show improvement but remain weak.
BofA analyst Jason Zemansky lowered the price target slightly from $30 to $29 but maintained a Buy rating. The analyst notes that upcoming Q4 earnings may have less impact than in prior years due to pre-announcements.
